General
Preferred name
SORAFENIB
Synonyms
SORAFENIB TOSYLATE ()
BAY-43-9006 ()
BAY-439006, Nexavar ()
Sorafenib tosilate ()
[11C]-Sorafenib, Sorafenib Tosylate, BAY-54-9085, BAY-43-9006, Nexavar ()
BAY-439006 ()
BAY 43-9006 ()
Sorafenib (D3) ()
Bay 43-9006 (D3) ()
Sorafenib-d3 ()
Sorafenib (Tosylate) ()
Bay 43-9006 (Tosylate) ()
BAY 43-9006 tosylate,NSC-724772 tosylate ()
NSC-724772,BAY 43-9006 ()
Bay 43-9006 D3, CM-4307 ()
Sorafenib (BAY 43-9006) tosylate ()
Sorafenib (BAY 43-9006) ()
Donafenib (Sorafenib D3) ()
donafenib ()
Sorafenib tosylateNexavarSorafenibBAY 43-9006 (free base)BAY 54-9085 (tosylate salt)N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamideSFN ()
NEXAVAR ()
CM-4307 ()
Sorafenib accord ()
BAY 54-9085 ()
BAY-54-9085 ()
Sorafenib-d3 ()
P&D ID
PD003493
CAS
284461-73-0
475207-59-1
1130115-44-4
Tags
available
probe
obsolete probe
drug
drug candidate
Approved by
EMA
FDA
First approval
2005
Drug indication
Renal cell carcinoma
Hepatocellular carcinoma
Neoplasm
Myelodysplastic syndrome
Drug Status
approved
investigational
Max Phase
3.0
4.0
Probe info
Probe type
calculated probe
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
81
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Sorafenib is a broad spectrum Type-2 kinase inhibitor targeting VEGFR2, VEGFR3, PDGFRβ, Flt3, and KIT and non-receptor kinases RAF1 and BRAF .
(GtoPdb)
PRICE
29
DESCRIPTION
Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFR¦Â, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].
DESCRIPTION
Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFR??, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.
DESCRIPTION
Sorafenib tosylate (Bay 43-9006 tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib tosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFR¦Â, FLT3 and c-Kit, respectively. Sorafenib tosylate induces autophagy and apoptosis. Sorafenib tosylate has anti-tumor activity. Sorafenib tosylate is a ferroptosis activator[1].
PRICE
29
DESCRIPTION
Donafenib (CM-4307) is a deuterated derivative of the approved multikinase inhibitor . Like sorafenib, it is orally active. Deuteration improves the stability of drug molecules thus extending half-life and increasing systemic exposure. This means that the effective drug dose may be shifted downward, with an associated improvement in tolerability. The medical formulation is donafenib tosylate.
(GtoPdb)
DESCRIPTION
inhibitor of BRAF, CRAF, and VEGFR2
(Informer Set)
DESCRIPTION
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
(PKIDB)
DESCRIPTION
Potent and selective MEK inhibitor; orally bioavailable
(Tocris Bioactive Compound Library)
DESCRIPTION
Sorafenib is a kinase inhibitor used in the treatment of unresectable liver carcinoma and advanced renal carcinoma.
(Enamine Bioactive Compounds)
DESCRIPTION
Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).
(TargetMol Bioactive Compound Library)
DESCRIPTION
Donafenib(Bay 43-9006 (D3)) is a deuterium-labeled Sorafenib which is a multikinase inhibitor(IC50s: 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively).
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
374
Organisms
10
Compound Sets
40
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
Informer Set
Ki Database
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
NPC Screening Collection
Obsolete Compounds
PKIDB
Probe Miner (suitable probes)
ReFrame library
Selleckchem Bioactive Compound Library
Tocris Bioactive Compound Library
Welcome Trust Cancer Drugs
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
84
Molecular Weight
464.09
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
3
cLogP
5.55
TPSA
92.35
Fraction CSP3
0.1
Chiral centers
0.0
Largest ring
6.0
QED
0.46
Structural alerts
3
aggregator (Aggregator Advisor)
Aggregators
historic compounds (Chemical Probes.org)
Obsolete
aggregator (ZINC)
Aggregators
Related compounds
Custom attributes
(extracted from source data)
Target
BRAF
FLT3
KDR
RAF1
Serine/threonine-protein kinase B-raf
PDGFRA, PDGFRB, KDR, KIT, FLT3
Tyrosine-protein kinase receptor FLT3
Vascular endothelial growth factor receptor
Stem cell growth factor receptor
Platelet-derived growth factor receptor beta
Tyrosine-protein kinase receptor RET
Serine/threonine-protein kinase RAF
Raf-1
b-RAF
VEGFR3
mPDGFR¦Â
PDGFR¦Â
BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET
Raf inhibitor
Apoptosis related,Autophagy,c-Kit,Ferroptosis,FGFR,FLT3,PDGFR,Raf,VEGFR
Apoptosis related,Autophagy,Ferroptosis,FLT3,PDGFR,Raf,VEGFR
Raf,VEGFR
FLT4
PDGFRB
KIT
FGFR1
RET
FLT1
Ferroptosis
B-Raf (V599E)
mPDGFRβ
PDGFRβ
VEGFR2/Flk1
VEGFR2/Flk2
Compound status
FDA
Pathway
RTK signaling
Angiogenesis
Apoptosis
Autophagy
MAPK
Tyrosine Kinase/Adaptors
MAPK/ERK Pathway
Protein Tyrosine Kinase/RTK
MOA
receptor protein-tyrosine kinase inhibitor
c-Kit
FLT
PDGFR
Raf
VEGFR
Inhibitor
FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor
Targets
RAF1,BRAF
Primary Target
Raf Kinases
Indication
renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)
Therapeutic Class
Anticancer Agents
Source data
